Filing Details

Accession Number:
0001415889-25-003515
Form Type:
4
Zero Holdings:
No
Publication Time:
2025-02-10 17:32:05
Reporting Period:
2025-02-06
Accepted Time:
2025-02-10 17:32:05
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1672619 Enliven Therapeutics Inc. ELVN Pharmaceutical Preparations (2834) 811523849
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1967163 Anish Patel C/O Enliven Therapeutics, Inc.
6200 Lookout Road
Boulder CO 80301
Chief Operating Officer No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2025-02-07 6,667 $21.93 329,977 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2025-02-06 171,000 $0.00 171,000 $22.47
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
171,000 2035-02-06 No 4 A Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on September 30, 2024 by the Reporting Person and by The Patel / Dong Family Trust Dated August 24, 2017, for which the Reporting Person serves as trustee (the "Patel / Dong Family Trust").
  2. This transaction was executed in multiple trades at prices ranging from $21.655 to $22.39. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  3. The shares are held by The Patel / Dong Family Trust.
  4. 1/4th of the shares subject to the option will vest on February 6, 2026 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.